Please login to the form below

Not currently logged in
Email:
Password:

CHMP recommends Erbitux

Merck Serono has announced that the Committee for Medicinal Products for Human Use has given a positive recommendation for an application to extend the uses of its cancer drug, Erbitux
Merck Serono has announced that the Committee for Medicinal Products for Human Use (CHMP) has given a positive recommendation for an application to extend the uses of its cancer drug, Erbitux.

The drug has already been approved for the treatment of colorectal cancer (CRC) in Europe and was licensed for use on the market in June 2004. Merck and Serono hope to extend the use of Erbitux to include the treatment of metastatic colorectal cancer (mCRC) with KRAS wild-type tumours, and is to be used in combination with chemotherapy.

The company, a division of global pharmaceutical manufacturer and developer, Merck, said that the scientific committee at the European Medicines Agency (EMEA) also gave its backing for the application.

Dr Wolfgang Wein, executive vice-president of oncology at Merck, said: "The positive opinion from the CHMP is an important step forward in the management of CRC and a step closer to tailored therapy for cancer patients."

30th May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics